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TNFa, also called cachectin, and TNF/3, alsocalled lymphotoxin, arepleiotropic
cytokinesthat can mediate a wide variety ofbiological effects. TNFa is mostly pro-
duced by activated macrophages, whereas TNF(3 is produced by activated lympho-
cytes (1, 2). These two cytokines are similar both in amino acid sequence and in
inducing similarbiological effects (3, 4). TNFci inducescytotoxicity in varioustumor
cells (5), stimulates the growth of fibroblasts (6), and regulates the functions ofen-
dothelial cells (7), neutrophils (8), T cells (9), B cells (10), as well as NK/LAK-cells
(11). TNFa interactswith avariety oftarget cellsby first bindingto a specific mem-
brane receptor thatcan be upregulatedby treatmentwith IFN-'Y (12). Thebiochem-
ical characteristics of the TNF receptor are still unclear. However, crosslinking ex-
perimentswith radiolabeled TNFaindicatedthe presence ofat least two polypeptides
associated with the TNF receptor (13, 14). Recently, mAbs against human TNF
receptor proteins purified from HL-60 cells were prepared (Brockhaus, M., and H.
Loetscher, manuscript submitted for publication). Three ofthese antibodies (htr-1,
htr-5, and htr-9) were selected for further studies. In this article we present results
on their bindingpatternto U937 cells andbiological effectson U937, Fs4 fibroblast,
and endothelial cells. The results demonstrate that htr-9 binds to U937 cells and
that this bindingcan be blockedbypretreatingthecellswithTNFaorTNF)3, whereas
htr-5 binding was inhibited byTNFabutonly toa minimalextent byTNFapretreat-
ment. Furthermore, htr-1 and htr-9, but not htr-5, were found to mimic TNFa
action on U937 cells, Fs4 fibroblasts, and endothelial cells. The data indicate that
these antibodies recognize structures ofa TNF receptor that are involved in signal
transduction and structures that differentiate between TNF-a and TNF0 binding
to target cells.
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Materials- and Methods
CytokinesandAntibodies.
￿
rTNFa andrTNF13weregenerously provided byGenentech Inc.
(South San Francisco, CA) andhad specific activities of 7.6 x 10' Wing and 10 x 107 U/mg,
respectively, as determined in the L-M bioassay (15). The generation ofmAbs htr-1, htr-5,
andhtr-9 against human TNFreceptor proteins isdescribedelsewhere(Brockhaus, M., and
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H. Loetscher, manuscript submitted for publication). The htr-5 and htr-9 are both of IgGl
isotype and htr-1 is an IgM antibody. These antibodies were affinity purified from hybridoma
supernatants by using rabbit anti-mouse Ig linked to Sepharose 4B (Pharmacia Fine Chem-
icals, Uppsala, Sweden). rTNFa and affinity-purified htr-5 and htr-9 were for some experi-
ments labeled with biotin as previously described (16). The pfa-11, an IgG, mouse mAb that
recognizes human platelet-derived growth factor A chain, was used as a control. Streptavidin-
phycoerythrin was purchased from Becton Dickinson & Co., Mountain View, CA.
Flow Cytometric Quantification of TNF Receptor Antibody Binding andrTNF-a Binding.
￿
U937
and HL-60 cells (American Type Culture Collection, [ATCC], Rockville, MD) were grown
in RPMI 1640 (Gibco Laboratories, Paisley, Scotland) supplemented with 10% heat-inactivated
FCS (Gibco), 2 MM r.-glutamine, and 40 Fig/ml gentamicin (complete RPMI 1640). Binding
ofTNF receptor antibodies or rTNFci to cells was done by adding 10 tog/ml of biotinylated
antibodies or 50 ng/ml of biotinylated rTNFa (BrTNFa) diluted in PBS with 0.1% BSA
(Sigma Chemical Co., St. Louis, MO) to 106 cells for 45 min at 0-4°C. The cells were then
washed twice in PBS/BSA and were stained with 20 1A of streptavidin-phycoerythrin for 45
min at 0-4°C. The cells were subsequently washed once in PBS and fixed in 2% formalin
(Merck, Darmstadt, Federal Republic ofGermany) and stored at 0-4 °C untilthey were ana-
lyzed using a FACScan flow cytometer (Becton Dickinson & Co.). Blocking experiments were
done by pretreating cells with one of the following reagents: 50 Ftg/ml of rTNFa, 50 Ftg/ml
ofrTNF0, 10,ug/ml ofhtr-9 or htr-5 for 45 min at 0-40C before addition of the biotinylated
reagent. For flow cytometric analysis 5 x 10' cells were acquired by list mode and measure-
ments were performed on a single cell basis and were displayed as frequency distribution
histograms.
Cytotoxicity Assay.
￿
About 3 x 106 U937 cells were labeled with 300 uCi Na?'Cr04 (Amer-
sham, Buckinghamshire, UK) for 90 min at 37°C, followed by two washes in RPMI 1640
and one wash in complete RPMI 1640. 100 Al of labeled U937 cells (105 cells/ml) in com-
plete medium were added to flat-bottomed microtiter plates (Costar, Cambridge, MA) to-
gether with 100 ul of different dilutions of TNF receptor antibodies or rTNFa . After 20 h
ofincubation at 37°C, 100,u] of supernatants were harvested and theirradioactivity was mea-
sured in an LKB Wallac 1270 gamma counter (Turku, Finland). Percent specific lysis was
calculated as follows: percent specific lysis = 100 x [(A-B)/(C-B)]. where A represents cpm
from test supernatants; B represents cpm from supernatants with target cells alone (sponta-
neous release); and C represents cpm after lysis of target cells with 0.250 /0 SDS (maximum
release). Results are presented as the mean ± SE of triplicate cultures. Spontaneous release
from U937 cells alone was <25% for all experiments.
ThymidineIncorporation Assay.
￿
Fs4 fibroblasts (generously provided by Dr. J. VWek, New
York University, New York, NY) were grown in complete RPMI 1640. 100 Al of 105 cells/ml
were dispensed in triplicate wells in flat-bottomed microtiter plates (Costar) together with
100 p.l ofdifferent dilutions ofTNF receptor antibodies or rTNFci. After 72 h of incubation
1 ttCi methyl-['H]thymidine (Amersham) was added to each well 4 h before harvesting the
cultures with a Titertek cell harvester (Flow Laboratories, Ayrshire, UK). Radioactivity was
measured by liquid scintillation counting in an LKB Wallac 1215 beta counter. Results are
presented as cpm t SE of triplicate cultures.
Human Endothelial Cell Cultures andAssays.
￿
Human endothelial cells (HEC)were obtained
by collagenase (Sigma Chemical Co.) treatment of human umbilical cord veins as described
(17). The identity ofHEC was confirmed as detailed in a previous report (18). The cells were
seeded at uniform density (0.15 x 106/well) in 24-well plates (Costar) using complete RPMI
1640. For the induction of IL-6, cultures ofconfluent HEC monolayerswere incubated with
or without the addition of different concentrations of TNF receptor antibodies or rTNFa.
After 24 h ofincubation the supernatants were collected and tested for IL-6 activity as detailed
previously (18). For adhesion of HL-60 cells, cultures of confluent HEC monolayers were
subjected to treatment with TNF receptor antibodies or rTNFa for 5-6 h at 37°C. HEC
monolayers were then washed twice with HBSS (Gibco) and each culture received 250 J1
of complete RPMI 1640 containing 0.5 x 105 "Cr HL-60 (HL-60 were labeled with "Cr
and washed as described above). After 1 h of incubation nonadherent "Cr HL-60 cells were
removed and after four washes with HBSS HEC cultures received 250 Al of 1% Triton-100(Sigma Chemical Co.) and were further incubated for 1 h to lyse the cells. The radioactivity
was determined by counting aliquots ofcell lysate using LKB Wallac 1270 gamma counter.
Maximum count was obtained from 0.1% Triton-100-treated 0.5 x 105 "Cr HL-60 cells.
The mean cpm as a reflection of "Cr HL-60 adherence is expressed as percentage of the
mean maximum cpm.
Results
Specificity of Binding of TNF Receptor Antibodies to U937 Cells.
￿
Experiments were
carried out to quantify the binding of htr-9 and htr-5 to U937 cells and to see if
rTNFa or rTNF(3 could inhibit the binding oftheseTNF receptor antibodies. The
results are shown in Fig. 1 and demonstrate that biotinylated (B) htr-9 significantly
bound to U937 cells and that pretreatment ofthe cellswith either rTNFa or rTNF#
reduced the binding almost to background level (Fig. 1, A and B). These data indi-
cate that htr-9 recognizes an epitope of a TNF receptor that is common for TNFa
and TNFj6 binding. Similar experiments were also performed with htr-5. As shown
in Fig. 1, C and D, pretreatment of the cells with rTNFa reduced the binding of
Bhtr-5 to background levels; however, pretreatment with rTNF0 only minimally
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FIGURE 1.
￿
Flow cytometric analysis of U937 cells stained with 10 Kg/ml of Bhtr-9 (A, B) or
10 wg/ml ofBhtr-5 (C, D). Where indicated, U937 cells were pretreatedwith 50 wg/ml ofrTNFa
(A, C) or 50 /eg/ml rTNF# (B, D) before addition ofthe biotinylated antibodies. The dotted histo-
grams represent the background staining obtained with the streptavidin-phycoerythrin reagent
alone.
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reduced Bhtr-5 binding. These results suggest that htr-5 recognizes an epitope of
a TNF receptor that is mainly involved in binding of TNF-a but to a lesser extent
TNF(3. The structural differences among the epitopes of the TNF receptor as rec-
ognized by htr-9 and htr-5 were further studied in another set of blocking experi-
ments. U937 cells were pretreated with htr-1 or htr-5 antibodies and thereafter stained
with Bhtr-9 before they were analyzed by flow cytometry. The results are shown
in Fig. 2, A and B and demonstrate that htr-1 and htr-5 inhibited the binding of
Bhtr-9. These data indicate that htr-9 recognizes an epitope of a TNF receptor that
is overlapping with epitopes recognized by htr-5 and htr-1. A similar experiment
was done to examine the bindingof Bhtr-5 after pretreatment with htr-1 and htr-9.
It wasfound that htr-9 didnot inhibit thebinding of Bhtr-5, whereas htr-1 inhibited
the Bhtr-5 binding (Fig. 2, C and D). This indicates that the epitope recognized
by htr-5 is not identical to that recognized by htr-9. The results in Figs. 1 and 2
are summarized in a qualitative manner in Table I.
Ejects of TNFReceptorAntibodies on BrTNF-ct Bindingto U937 andHL-60 Cells.
￿
As
htr-5 was found to inhibit the binding of Bhtr-9, it was of interest to see if this anti-
body also inhibited BrTNFa binding. U937 and HL-60 cells were pretreated with
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FIGURE 2.
￿
Flow cytometric analysis of U937 cells stained with 10 ug/ml of Bhtr-9 (A, B) or
10 ug/ml Bhtr-5 (C, D). Where indicated, U937 cells were pretreated with 10 ug/ml htr-5 (A),
htr-1 (B, D) or htr-9 (C) before addition of thebiotinylated antibodies. The dotted histograms
represent the background staining obtained with the streptavidin phycoerythrin reagent alone.J
J
W
U
O
W
m
z
ESPEVIK ET AL.
￿
41 9
TABLE I
Specificity of Binding of TNF Receptor Antibodies to U937 Cells
Binding was determined by flow cytometry andthe table is aqualitative sum-
mary of the results in Figs. 1 and 2 .
$ Data not shown.
rTNFa or htr-5 and thereafter stained with BrTNFa and analyzed by flow cytom-
etry. As shown in Fig. 3 A htr-5 only minimally inhibited the binding of BrTNFa
to U937 cells. However, htr-5was farmore effectiveto inhibitthe bindingofBrTNFa
to HL-60 cells (Fig. 3 B). Similar results were also obtained by usinghtr-9 pretreat-
ment (data not shown).
Biological Effects of TNF Receptor Antibodies on U937 Cells.
￿
The htr-1, htr-5, and
htr-9 antibodies bind to epitopes associated with a TNF receptor (Fig. 1). Efforts
B
BrTNF- a
HL-60
+rTNF-a
no addition
+htr-5
FLUORESCENCE INTENSITY (log)
FIGURE 3.
￿
Flow cytometric analysis of
U937 (A) and HL-60 cells (B) stained
with 50 ng/ml of BrTNFa. Wherein-
dicated the cells were pretreated with
50 Wg/ml rTNRaor 10,ug/ml htr-5 be-
fore addition of BrTNF-a.
Binding' inhibited by:
Antibody TNF-a TNF-R htr-9 htr-5 htr-1
htr-9 Yes Yes - Yes Yes
htr-5 Yes Minimally No - Yes
htr-12 Yes Minimally Yes No -420
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were therefore made to determine whether these antibodies could mimic or block
the biological effects ofTNFa in different target cell systems. The htr-1, htr-5, and
htr-9 antibodies were first tested if they had any cytotoxic activity on U937 cells.
The results shown in Fig. 4 demonstrate that htr-1 and htr-9 induced a high degree
of cytolysis, whereashtr-5 was ineffective in this respect. When compared in molar
terms, -103 to 104 times more ofhtr-9 than rTNFa was needed in order to mediate
a comparable level of cytolytic activity. The IgM antibody, htr-1, was -100 times
more effective than htr-9 in inducing cytotoxicity of U937 (Fig. 4). These data sug-
gest that htr-1 and htr-9 recognize an epitope of a TNF receptor that is involved
in inducing the cytotoxic activity of TNFa. As the binding studies indicated that
htr-5 inhibited htr-9 binding, it was of interest to examinewhetherhtr-5 could also
inhibit the cytotoxic activity ofhtr-9. Cytotoxicity mediated by htr-9was subsequently
determined in the absence and presence of 1014g/ml htr-5. As expected, htr-5 com-
pletely inhibited the cytotoxic activity of htr-9 (Fig. 4 B). It was also tested if htr-5
was able to inhibit the cytotoxic action of rTNFa. The results in Fig. 5 revealed
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FIGURE 4. (A) Cytotoxic ef-
fectsofTNFreceptor antibodies
(htr-1, htr-5, andhtr-9) on U937
cells. The bioactivity of htr-1
was diluted out between 0.01
and0.1 ng/ml(datanot shown).
(B) Inhibition ofhtr-9 induced
cytotoxicity on U937 cells with
htr-5 antibodies. Cytotoxicity
was determined in a20-h "Cr-
release assay in the absence
or presence of 10 ug/ml htr-5
(+ htr-5).
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FIGURE 5.
￿
Inhibition of rTNFa
inducedcytotoxicity on U937 cells
with htr-5antibodies. Cytotoxicity
was determined in a 20-h SiCr-
releaseassayin theabsence(-htr-
5) or presence of 10 Wg/ml htr-5
(+htr-5).
that htr-5 did not completely inhibit the cytotoxicity, but shifted the rTNFa dose-
responsecurveti10-fold. The control antibody pfa-11 did not inhibit htr-9- orTNF-
a-mediated cytolysis (data not shown).
BiologicalEffects ofTNFReceptorAntibodies on Fs4Fibroblasts.
￿
The different biolog-
ical effects ofTNFa depend on the target cells used. It was therefore of interest
to see ifthe TNF receptor antibodies also could mimic the growth-stimulating ac-
tivity ofTNFci onhuman Fs4 fibroblasts. Both htr-1 and htr-9inducedadoserelated
increase in thymidine incorporation in Fs4 cells (Fig. 6 A). In contrast, htr-5 did
not have any effect on thymidine incorporation (Fig. 6 A). Also in this system, htr-1
was the most effective antibody in mimicking TNFa activity (Fig. 6 A). Approxi-
mately 102 times more ofhtr-9 than rTNFa was needed in order to obtain com-
parable proliferative activities (data not shown). As was the case with U937, htr-5
was able to completely block the proliferative activity induced by htr-9 on Fs4 cells
(Fig. 6 B). In contrast, rTNFa induced proliferation of Fs4 cells was not affected
byhtr-5 treatment (datanot shown). Thesedata suggest that the epitope recognized
byhtr-9 antibody is involved inTNFasignal forstimulating the growth ofFs4cells.
Biological Effects ofTNFReceptor Antibodies on Human Endothelial Cells.
￿
The effects
ofTNF receptor antibodies on IL-6 production by HEC were studied in a direct
comparison withthe effects ofrTNFa and theresults are presentedin TableII. Con-
sistent with data reported recently (18) rTNFa caused a substantial stimulation of
IL-6 production after 24 h of incubation. While pfa-11 and htr-5 had little effects,
antibody h'tr-9 induced a marked increase in IL-6 production reaching 2.45 folds
greater thanthe amounts detected in control HEC cultures (Table II). The presence
ofhtr-1 also caused a marked enhancement of IL-6 production (not shown).
One ofthe important biological properties ofTNFci is its ability to increase the
adhesiveness ofHEC (19). Therefore, the ability ofhtr-9 antibody to mimic TNFci
effect was tested in an adhesion assay using "Cr HL-60 and the results are422
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(A) Effects ofhtr-1,
htr-5, and htr-9 antibodies on
proliferation of Fs4 cells. The
i
￿
antibodies were added to Fs4
1
￿
10
￿
cells for 72 h before incorpora
Antibody (Nyimi)
￿
tion of radioactive thymidine
was determined. (B) Inhibition
ofhtr-9-induced increasein pro-
liferation of Fs4 cells by htr-5
antibodies. Thymidine incorpo-
ration was estimated in the ab-
sence or inpresence of 10 mg/ml
htr-5 (+htr-5).
presented in Table III. HEC treated with htr-9 (0.1-1 14g/ml) showed an increased
adhesiveness similar to that observed after treatment with rTNFa as reflected by
the adherence of 51Cr HL-60 cells. Htr-5 did not have any effect on the adhesive-
ness. However, htr-5 was ableto completely blocktheeffect ofhtr-9 alsointhissystem.
Furthermore, htr-5 could partiallyinhibit rTNFa-induced adhesiveness. Thetreat-
mentofHEC monolayers withan irrelevant antibody, pfa-11, didnot haveany effect
(data not shown), indicating the specificity ofthe observed htr-9 effect. The results
presented in Tables II and III were confirmed in two additional experiments.
Discussion
In this study antibodies against a TNF receptor (htr-1, htr-5, htr-9) have been
used to studytheirbindingpattern to U937cells andtheirbiological effectsonU937
cells, Fs4 fibroblasts, and endothelial cells. The htr-1, htr-5, and htr-9 antibodiesESPEVIK ET AL.
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TABLE II
The Influence of Antibodies to TNFReceptor on IL-6 Production by HEC
Cultures ofconfluent HEC monolayers were incubated in duplicate with and
without the addition of various agents as indicated. After 24 h of incubation
the supernatants were collected andtested for IL-6 activity. Thedataare present-
ed as the mean of triplicate IL-6 determination. SD <10%. Stimulation in-
dexis calculated by dividing IL-6 values from test cultures by IL-6 values in
control cultures.
have been generated against partially purified TNFa binding proteins isolatedfrom
HL-60 cells, and all three antibodies recognize noncarbohydrate epitopes on the
extracellulardomain ofa human TNF receptor (Brockhaus, M., and H. Loetscher,
manuscript submitted forpublication). The properties ofthe molecules recognized
by these antibodies will be presented elsewhere (Brockhaus, M., and H. Loetscher,
manuscript submitted for publication). These TNF receptor antibodies are species
specific as they do not recognize TNF receptors on murine cells like WEHI 164
or L929 (Brockhaus, M., andH. Loetscher, manuscript submitted forpublication).
Thebinding specificity ofthese antibodieswasexamined by usingbiotinylated anti-
TABLE III
Adherence of HL-60 to Human Endothelial Cells (HEC) after
Treatment with Antibodies to a TNFReceptor
Cultures ofconfluent HEC monolayers were incubated in medium only and in
medium plus either rTNF-a, htr-9, or htr-5 as indicated. After 4 h, the cultures
were washed twice with HBSS and each culture received 105 5'Cr HL-60 in
0.25 ml medium andwas further incubated for 1 h. Nonadherent cells were aspi-
rated, the cultures were washed, and adherent 5'Cr HL-60 were lysed for de-
termination of retained radioactivity. Each treatment wasperformed in duplicate
and the data are presented as mean cpm from four lysate aliquots counted .
Agent added to
HEC cultures IL-6
Stimulation'
index
pglmt
None 180 1 .0
rTNF-a 10 U/ml 509 2 .83
rTNF-a 100 U/ml 801 4.45
Htr-9 0.25 ug/ml 342 1 .90
Htr-9 2 .50 Wg/ml 432 2 .40
Htr-5 0.25 ug/ml 287 1 .59
Htr-5 2.50 jug/ml 227 1 .26
Pfa-11 2.5 Ag/ml 220 1 .22
Treatment of HEC cultures Percent adherence of HL-60
None 4
rTNF-a (10 U/ml) 96
Htr-9 (0.1 ug/ml) 47
Htr-9 (1 hg/ml) 73
Htr-5 (1 ug/ml) 5
Htr-9 (0.1 Wg/ml) + htr-5 (1 ug/ml) 6
Htr-9 (1 Rg/ml) + htr-5 (1 ug/ml) 6
rTNF-a (10 U/ml) + htr-5 (1 ug/ml) 69424
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bodies and flow cytometric quantification. htr-5 and htr-9 both bound tothe plasma
membrane of U937 cells. Inhibition ofthe binding by pretreatment with rTNFa
demonstrated the specificityoftheseantibodies fortheTNF receptor. Furthermore,
the binding studies demonstrated that htr-9 recognized an epitope that was shared
by htr-5 and htr-1, while htr-5 recognized an epitope that was shared by htr-1 but
not byhtr-9. Themost likely explanationofthese resultsisthathtr-5and htr-9 recog-
nize twodifferent but spatially relatedepitopes on the same TNFreceptor molecule.
It is unclear whether the epitopes recognized by htr-1 and htr-9 are identical. The
result that htr-1, but not htr-9, inhibited htr-5 binding could be due to the fact that
htr-1 is an IgM antibody that is larger than htr-9 and thereby can cause steric hin-
drance for htr-5 binding.
To our surprise we found thatTNF0 didnot reduce the binding ofhtr-5 to U937
cells to the same extent as TNFa did. Many ofthe biological activities ofTNFa
are shared by TNF0(3, 4). However, there aredifferencesbetweenTNF-ci andTNFQ
activities in some systems. In human endothelial cells a higher dose ofTNF0 is
needed compared with TNFa in order to induce similar activities (20). Aggarwal
et al. have found that TNF-ci and TNF0 compete with "5ITNFa for binding to
the same receptor (12). The finding that htr-9 binding was blocked by rTNFoi and
rTNF/3 is consistent with the presenceofacommon receptor forboth forms ofTNF.
However, the presence ofspecificepitopes foreach cytokine is evidentfrom ourbinding
studies with htr-5. These epitopes may determine the affinity ofeach cytokine for
corresponding receptor-cytokine interaction.
Wehavedemonstrated that the htr-1 andhtr-9antibodies,againstthe TNF receptor
mimic the action of rTNFa on U937 cells, Fs4 fibroblasts, and endothelial cells.
The htr-5 antibody had no TNF-ci activity in these systems. However, htr-5 com-
pletelyinhibited thebiological activity ofhtr-9 on U937 cellsand on Fs4 fibroblasts.
These results further give support to the observation that htr-5 and htr-9 recognize
differentbutoverlappingepitopes oftheTNF receptor. Furthermore, thedatastrongly
indicate that a common epitope ofaTNF receptor is involved in inducing cytotox-
icity oftumor cells, proliferation offibroblasts, and activation of endothelial cells
forIL-6 production and tumor cell adherence. The biological activities ofhtr-1 and
htr-9 were different thanthe recentlydescribedantibody(anti-Fas) that wasreported
to recognize an antigen associated with a TNF receptor and that killed cells that
were not susceptible to the cytolytic action of TNF-ci (21). Our data suggest that
htr-1 and htr-9 detect an epitopeofaTNFreceptor that is present on TNFsensitive
U937 cells, Fs4 fibroblasts and endothelial cells and induce TNFa activity. The
results showingTNFlike activity for the antibody htr-9 are in accordance with the
observation that the same antibody as well as TNF activate the transcription factor
NFKB in the nuclei of HL-60 and HEp2 cells (Hohmann, H., H. Loetscher, M.
Brockhaus, R. Remy, and A. P G. M. van Loon, manuscript submitted for publi-
cation).
The bindingstudies with BrTNFa revealed that pretreatment with htr-5 or htr-9
only partially reduced BrTNFci binding to U937 cells, whereas the inhibition of
BrTNFa binding by htr-5 or htr-9 pretreatment was much more pronounced in
HL-60 cells. In addition, htr-5 onlypartiallyinhibited thebiological activity ofTNFa
on U937 and endothelial cells but not on Fs4 cells. These results could be due to
thefarloweraffinityoftheantibodies fortheTNFreceptor compared withtheligand.ESPEVIK ET AL.
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It is also possible that TNF receptors other than the one recognized by htr-5 and
htr-9 are involved in binding and signaling of TNFa in different cell types. The
data also suggest that there are differences between cell types with regard to expres-
sion of TNF receptors as HL-60 cells express more of the receptor recognized by
htr-5 compared with U937 cells. These results are in accordance with Brockhaus
and Loetscher (manuscript submitted for publication) who have identified two types
of TNF receptors on human cell lines by using mAbs. The functional relationship
between the apparently different TNF receptor types is not clear and requires fur-
ther studies.
Summary
Three different antibodies against a human TNF receptor (htr-1, htr-5, and htr-
9) have been examined for their binding pattern to U937 cells and ability to mimic
TNFa activity in U937 cells, Fs4 fibroblasts, and human endothelial cells. Flow
cytometric analysis revealed that htr-5 and htr-9 bound specifically to a TNF receptor
on U937 cells that could be blocked by pretreatment with rTNFa. Pretreatment
of U937 cells with rTNF(3 blocked the binding of htr-9, but to a lesser extent htr-5
binding. Pretreatment with htr-5 inhibited the binding of htr-9 to U937 cells while
pretreatment with htr-9 did not inhibit htr-5 binding. These results indicate that
htr-5 and htr-9 recognize distinct but overlapping epitopes ofa human TNF receptor
on U937 cells and that htr-5may be close to a TNFa-specific domain ofthe binding
site. Pretreatment with htr-5 or htr-9 only minimally reduced binding of BrTNF-a
to U937 cells; however, these antibodies were much more effective in inhibiting BrTNF
a binding to HL-60 cells. Furthermore, it was found that htr-1 and htr-9, but not
htr-5, had TNFci activity on U937 cells, Fs4 fibroblasts, and endothelial cells and
that the TNFa activity induced by htr-9 was completely inhibited by htr-5. How-
ever, the cytotoxic activity of TNFci was only partially inhibited by htr-5 on U937
cells while htr-5 had no effect on TNFci activity on Fs4 cells. The data suggest that
a common epitope is involved in inducing TNFa activity in three different cell systems.
Receivedforpublication 21 August 1989 andin revisedform 16 October 1989.
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